Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5JTW2
UPID:
CEP78_HUMAN
Alternative names:
-
Alternative UPACC:
Q5JTW2; A1A4S8; E9PHX5; Q5BJE3; Q5JTW0; Q5JTW1; Q9H9N3
Background:
Centrosomal protein of 78 kDa (Cep78) is pivotal in cellular processes, notably for its role in centrosome localization and centriole duplication, facilitated by PLK4. It is also implicated in cilium biogenesis, essential for cell signaling and development. The protein's involvement in these critical cellular functions underscores its importance in maintaining cellular integrity and function.
Therapeutic significance:
Cep78's association with Cone-rod dystrophy and hearing loss 1, a disease characterized by progressive vision and hearing loss, highlights its potential as a therapeutic target. Understanding the role of Centrosomal protein of 78 kDa could open doors to potential therapeutic strategies, offering hope for interventions in diseases marked by sensory loss.